Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLIE: lenvatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in relapsed or refractory osteosarcoma
2019-003696-19Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib, ifosfamide and etoposide in osteosarcoma (OS) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Progression-free survival. Started Dec 2019; status: completed.
02
Drugs
lenvatinibifosfamideetoposide
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2019-003696-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003696-19.